Objective:To explore the expression of B7-H4 in prostate cancer tissue and its value as a prognostic biomarker for poor survival. Methods:The protein expression of B7-H4 was measured by immunohistochemistry assay in 72 prostate cancer tissues and 50 benign prostatic hyperplasia tissues, the relationship between B7-H4 expression and over-all survival in prostate cancer patients was identified by Kaplan-Meier, the prognostic factors of patients were calculated by Cox proportional hazard regression model. Results:The high expression rate of B7-H4 in the prostate cancer group was 83.3% (60/72), while 32.0% (16/50) in the prostatic hyperplasia group, the high expression rate of B7-H4 in the prostate cancer group was significantly lower than that in the prostatic hyperplasia group, the difference was statistically significant (χ2=33.105, P<0.001). The high expression rate of B7-H4 in the 8-10 score group was markedly than that in the 2-7 score group, it was higher in Ⅲ-Ⅳ group than in the Ⅰ-Ⅱ group, also it was obviously higher in lymph node metastasis group was obviously higher than in the non-lymph node metastasis group, the difference was statistically significant (P<0.05). The median survival in the prostate cancer patients was negatively correlated with the Gleason score, TNM stage, lymph node metastasis and B7-H4 expression (all P<0.05). Besides, Gleason score, TNM stage, lymph node metastasis and B7-H4 were independent risk factors for the poor prognostic of prostate cancer (all P<0.05). Conclusion:The expression of B7-H4 is up-regulated in the prostate cancer, and its can be used as a biomarker for prognostic of prostate cancer patients.
 VERMASSEN T,VAN PRAET C,VANDERSCHAEGHE D, et al.Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer[J]. Electrophoresis,2014,35(7):1017-1024.
 DARMOCHWAL-KOLARZ D,KLUDKA-STERNIK M,KOLARZ B, et al.The expression of B7-H1 and B7-H4 co-stimulatory molecules on myeloid and plasmacytoid dendritic cells in pre-eclampsia and normal pregnancy[J]. J Reprod Immunol,2013,99(1-2):33-38.
 ZHANG L,WU H,LU D, et al.The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus[J]. Oncogene,2013, 32(46):5347-5358.
 LIANG M,LI J,WANG D, et al.T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province[J]. Tumour Biol,2014,35(1):55-60.
 QIAN Y,HONG B,SHEN L, et al.B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells[J].Cell Tissue Res,2013,353(1):139-151.
 THOMPSON R H,KWON E D,ALLISON J P. Inhibitors of B7-CD28 costimulation in urologic malignancies[J]. Immunotherapy,2009,1(1):129-139.
 DANGAJ D,LANITIS E,ZHAO A, et al.Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses[J]. Cancer Res, 2013,73(15):4820-4829.
 CHEN C,QU QX,SHEN Y, et al.Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages:A potential mechanism of immune escape[J]. Cancer Lett,2012,317(1):99-105.
 DARMOCHWAL-KOLARZ D,SERAFIN A,TABARKIEWICZ J, et al.The expressions of co-stimulatory molecules are altered on putative antigen-presenting cells in cord blood[J]. Am J Reprod Immunol,2013,69(2):180-187.
 XU Y,ZHU S,SONG M, et al.B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma[J]. Oncol Lett,2014,7(5):1474-1478.